BiotechTube

enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Transitional Cell

Conditions

Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms

Trial Timeline

Oct 11, 2017 → Sep 11, 2026

NCT ID
NCT03288545

About enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine

enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine is a phase 1/2 stage product being developed by Astellas Pharma for Carcinoma, Transitional Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03288545. Target conditions include Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03288545Phase 1/2Active

Competing Products

20 competing products in Carcinoma, Transitional Cell

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
Cemiplimab + CetuximabEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
25
BB-401Benitec BiopharmaPhase 2
44
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
AzenosertibZentalis PharmaceuticalsPhase 2
44
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
Ramucirumab + PaclitaxelEli LillyPhase 2
52
LY2875358 + ErlotinibEli LillyPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85